|
**Overview**: Aspergillus IgG IgM Panel**Introduction**: The Aspergillus IgG IgM Panel is a diagnostic tool designed to screen for Aspergillus infection using serum samples. In India, aspergillosis (including invasive, chronic pulmonary, and allergic forms) is common in immunocompromised patients, those with chronic lung disease, or post-TB sequelae, with prevalence high in humid/monsoon regions and among diabetics (aspergilloma in 10-20 percent of cavitary TB cases). Symptoms include cough, hemoptysis, fever, weight loss, or respiratory failure. High morbidity from underdiagnosis in rural areas, overlap with TB/infections, limited fungal testing, and delayed antifungal therapy leading to high mortality. Per immunology practices aligned with ICMR and Indian Chest Society guidelines, the test employs immunoassay for IgG/IgM detection over 1-2 days with high sensitivity/specificity, valuable for supporting diagnosis in suspected cases. This diagnostic falls under infection screening and targets patients with suspected aspergillosis, addressing accurate detection to guide voriconazole or amphotericin therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Aspergillus Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded for serological diagnosis; in India, prominence with TB sequelae burden.**Purpose**: The test screens for 2 parameters including Aspergillus IgG and IgM to guide infection assessment, detect acute/chronic exposure, inform antifungal therapy.**Test Parameters**: 1. Aspergillus IgG, 2. Aspergillus IgM.**Pretest Condition**: No fasting required; patients should report cough, hemoptysis, fever, or lung disease history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lung symptoms, TB history, immunosuppression, diabetes, or environmental exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated aspergillosis including respiratory failure, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgG/IgM indicates Aspergillus exposure/infection, necessitating specialist input. Negative may require follow-up if suspicion persists.**Specialist Consultation**: Pulmonologists or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: Galactomannan, culture, or CT chest for confirmation.**Test Limitations**: May not distinguish colonization from invasion; comprehensive approach required.**References**: Indian Journal of Chest Diseases 2024, Aspergillosis Studies India 2023. |
